Add to Favorites Newsroom RSS Share
New York, NY USA

Our News on Newswise

CRF Invites the NYC Community to Attend Free Seminar on the Link Between Diabetes and Heart Disease During American Heart Month


The Cardiovascular Research Foundation (CRF) will hold a free seminar, “The Link Between Diabetes & Your Heart,” on Wednesday, February 7, 2018 in New York City. The seminar, part of a series of Mini-Med School seminars conducted by the CRF...
18-Jan-2018 2:05 PM EST Add to Favorites

Study Evaluates Safety of Three-Month Versus Standard Twelve-Month Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome Treated with a Drug-Eluting Stent

Results from the prospective, multicenter, randomized investigator-initiated REDUCE trial were reported today at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research...
1-Nov-2017 6:05 PM EDT Add to Favorites

Study Finds Six Months of Dual Antiplatelet Therapy May be Non-Inferior to Twelve Months in STEMI Patients Receiving Drug-Eluting Stents

The first trial to evaluate the safety of dual antiplatelet therapy (DAPT) for less than 12 months in ST-elevation myocardial infarction (STEMI) found six months of DAPT was non-inferior to 12 months of DAPT among patients treated with...
1-Nov-2017 6:05 PM EDT Add to Favorites

Synergy Stent with Shorter DAPT Is Superior to a Bare-Metal Stent in Elderly Patients

Elderly patients undergoing PCI often receive bare-metal stents (BMS) instead of drug-eluting stents (DES) to shorten the duration of dual antiplatelet therapy (DAPT) and reduce bleeding risk. However, results from the SENIOR trial found that...
1-Nov-2017 6:05 PM EDT Add to Favorites

Thirty-Day Results of ABSORB IV Demonstrate that Improvements in Bioresorbable Stent Technology and Technique are Still Needed

Thirty-day results from ABSORB IV, the largest randomized everolimus-eluting bioresorbable vascular scaffold (BVS) trial to date, found BVS to be noninferior to a cobalt-chromium everolimus-eluting stent (CoCr-EES) for target lesion failure (TLF).
31-Oct-2017 5:05 PM EDT Add to Favorites

TAVR Found to be Cost-effective Compared with SAVR in Intermediate Risk Patients with Aortic Stenosis

Analysis of the PARTNER 2A trial and the SAPIEN-3 Intermediate Risk registry found transcatheter aortic valve replacement (TAVR) to be highly cost-effective compared with surgical aortic valve replacement (SAVR) in intermediate surgical risk...
31-Oct-2017 5:05 PM EDT Add to Favorites

Double Kissing Crush Two-Stent Technique in Left Main Bifurcation Lesions Demonstrates Lower Rates of Target Lesion Failure

A large-scale randomized trial examining the double kissing (DK) crush two-stent technique compared with provisional stenting (PS) in the treatment of true distal bifurcation lesions of the left main artery, found that the DK crush technique was...
30-Oct-2017 6:05 PM EDT Add to Favorites

Should Patients with Cardiogenic Shock Receive Culprit Lesion Only PCI or Multivessel PCI?

Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found that an initial strategy of culprit lesion only percutaneous coronary intervention (PCI) reduces the composite of 30-day mortality and/or severe renal failure in...
30-Oct-2017 5:05 PM EDT Add to Favorites

Our Experts on Newswise

CRF to Hold Free Seminar on Living with Heart Failure for Patients and Caregivers

CRF will hold a free seminar, “Broken Hearts: Living with Heart Failure,” on Tuesday, June 6, 2017 for heart failure patients and caregivers at NewYork-Presbyterian Hospital. The seminar will focus on providing both patients and caregivers a...
9-May-2017 12:05 PM EDT

Our YouTube Videos

Youtube feed not yet configured. Is this your Newswise member page? Contact to configure this module.

Chat now!